(secondQuint)Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers.

 This study will look at the safety and effectiveness of the investigational drug ponatinib in lung cancer.

 The investigators hope that ponatinib will work against tumors that have certain biomarkers.

 Therefore, the study will pre-screen patients for these certain biomarkers before enrolling them into the main treatment study.

 Different doses of ponatinib may be tested in this study.

.

 Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers@highlight

This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer.

 Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

